Meconium aspiration syndrome (MAS) is one of the top causes of severe respiratory failure in neonates. This study was designed to investigate the effective volume of therapeutic bronchoalveolar lavage (BAL) with diluted surfactant in the treatment of MAS in newborn piglets. Human meconium was instilled in 24 piglets to induce MAS, and the piglets were randomly divided into four groups: 1) control, no lavage; 2) lavage-10, BAL with diluted surfactant (5 mg/mL, Survanta) 10 mL/kg in two aliquots; 3) lavage-20, 20 mL/kg in two aliquots; 4) lavage-30, 30 mL/kg in two aliquots. Cardiopulmonary parameters were monitored, and the lung tissue was histologically examined after experiments. The changes in oxygenation and lung compliance of lavage-20 and lavage-30 groups were significantly better than control and lavage-10 groups (p Ͻ 0.05), but there was no significant difference between lavage-20 and lavage-30 groups. The lung injury scores were significantly lower in the dependent site of lavage-20 and lavage-30 groups than the other two groups. In conclusion, using 20 mL/kg diluted surfactant in two aliquots to perform therapeutic BAL was as effective as 30 mL/kg in improving the pathophysiological outcomes in MAS and may warrant consideration clinically in treating MAS. Despite improvement in immediate resuscitation at birth and the use of assisted ventilation, respiratory distress caused by aspirated meconium is difficult to manage. Even with innovative respiratory care, some neonates with severe MAS may become candidates for extracorporeal membrane oxygenation and high rates of mortality may occur (1-3).The mechanisms in pathogenesis of MAS typically includes local obstruction of the airway by meconium debris, with associated impairment of gas diffusion, patchy atelectasis, pulmonary vascular hypertension, pulmonary inflammation, chemical pneumonitis, and surfactant inactivity (4 -10). Bolus surfactant administration has been tested for the treatment of MAS previously, but no significant reduction in mortality and other morbidities was obtained (11)(12)(13)(14).Effective meconium removal without inactivating or washing out surfactant is a potential additional treatment for treating MAS. Theoretically, the concept of therapeutic bronchoalveolar lavage (BAL) involves dilution and removal of the meconium from the airspaces. Intervention to treat progressive MAS using BAL with saline has not proved to be clinically useful (15,16) and may even be detrimental as the volume of saline can further impede gas exchange and worsen lung mechanics. Some authors have tried to use bolus surfactant given after saline lavage (15,(17)(18)(19)(20), but the surfactant distribution was not uniformly obtained in the same manner as when using surfactant lavage (21,22).Recently, technique of therapeutic BAL with diluted exogenous surfactant has been tried and shown some promising benefits in improving pathophysiological responses, increasing meconium removal amount, lowering ventilation duration, and decreasing the severity of ill...